Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of EA8001 in Healthy Adult Subjects
jRCT2051260050Phase 1Not yet recruiting
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of evenamide in schizophrenia (4 arms), sponsored by EA Pharma Co., Ltd. Primary endpoints: Plasma concentrations of EA8001, Plasma concentrations of 3-BPAA and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
evenamide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2051260050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260050.